Optimize Neurology AIM Specialty Health Integration for Prior Authorization

Klivira's platform provides robust neurology AIM Specialty Health integration, simplifying the complex prior authorization landscape for high-cost therapies and advanced diagnostics in neurological care.

Revenue cycle directors and prior authorization coordinators in neurology face persistent challenges with high-volume, complex PAs for specialty drugs and advanced imaging. Integrating with specialty benefit managers, such as AIM Specialty Health, demands precise data exchange and adherence to specific clinical criteria to avoid delays and denials. Klivira streamlines this critical workflow.

The Intersection of Neurology PA and Specialty Benefit Management

Neurology prior authorizations frequently involve high-cost, specialty-managed medications and advanced diagnostic imaging. Specialty benefit managers, like AIM Specialty Health, play a crucial role in overseeing these authorizations, requiring detailed clinical documentation and adherence to specific medical policies. Klivira's integration capabilities are designed to navigate these complex requirements efficiently.

Key Neurology PA Triggers Managed by Specialty Benefit Organizations

MS disease-modifying therapies (DMTs) like ocrelizumab, natalizumab, and oral agents.
CGRP monoclonal antibodies for migraine prevention (erenumab, fremanezumab, galcanezumab).
Advanced imaging, including brain MRI, MR angiography, and amyloid PET scans.
Alzheimer's disease therapeutics such as lecanemab and donanemab, requiring specific biomarker confirmation.
Botox for chronic migraine, spasticity, and dystonia, with specific indication and trial requirements.

Streamlined AIM Specialty Health Integration for Neurology Workflows

Klivira facilitates seamless data exchange for neurology prior authorizations that fall under specialty benefit management, including those managed by AIM Specialty Health. Our platform automates the submission of clinical documentation, leverages X12 278 transactions for medical benefits, and supports NCPDP SCRIPT for pharmacy benefits, reducing manual effort and accelerating approval times for critical neurological treatments.

Critical Documentation for Neurology PAs

AAN Practice Guidelines compliance for MS DMTs, including McDonald criteria, EDSS scores, and MRI findings.
Amyloid confirmation (PET or CSF) and MRI for ARIA screening for Alzheimer's anti-amyloid antibodies.
Detailed headache diaries and documentation of prior preventive trial failures for CGRP migraine biologics.
Specific indication and prior medical therapy trials for Botox applications (e.g., chronic migraine criteria).
Neuropsychological evaluations and candidate selection criteria for neuromodulation devices like DBS.

Klivira's Impact on Neurology Prior Authorization Efficiency

Klivira's platform dramatically improves efficiency for neurology practices by automating the prior authorization process. We apply AAN-guideline-aware step-therapy logic for MS and CGRP therapies, automate diagnostic-biomarker documentation for Alzheimer's treatments, and provide robust tracking for periodic re-authorizations of chronic neurological medications. This reduces denial rates stemming from step therapy gaps or incomplete documentation.

EMR and Payer Touchpoints for Neurology PA Automation

Our platform integrates directly with leading EMR systems via SMART on FHIR, capturing relevant clinical data from order types and clinical templates. This data is then automatically formatted and submitted to specialty benefit managers and payers, often leveraging X12 278 for medical PAs or NCPDP SCRIPT for pharmacy PAs. This comprehensive approach minimizes manual data entry and ensures consistent, accurate submissions.

Frequently asked questions

How does Klivira handle step therapy requirements for MS DMTs with specialty benefit managers?

Klivira's platform incorporates AAN-guideline-aware step-therapy logic, automatically identifying and documenting prior treatment failures or exceptions required by payers and specialty benefit managers for MS disease-modifying therapies. This helps ensure compliance and reduces denials related to step therapy.

What specific neurology imaging PAs are streamlined through Klivira's integration?

Klivira streamlines prior authorizations for advanced neurological imaging, including brain MRI, MR angiography, and amyloid PET scans. Our system extracts necessary clinical details from EMRs and formats them for efficient submission to specialty benefit managers and payers, accelerating approval for critical diagnostics.

How does Klivira support documentation for Alzheimer's anti-amyloid therapies?

For Alzheimer's anti-amyloid antibodies like lecanemab, Klivira automates the collection and submission of critical documentation, including amyloid confirmation (PET or CSF), MRI findings for ARIA screening, and ApoE genotype results. This ensures all specific payer requirements for these complex therapies are met.

Can Klivira manage recurring neurology authorizations for chronic treatments?

Yes, Klivira is designed to manage periodic re-authorizations for chronic neurological treatments, such as many MS DMTs or Botox for chronic migraine. Our platform tracks authorization expiry dates and proactively initiates the re-authorization workflow, ensuring continuity of care and preventing lapses.

How does Klivira integrate with EMRs for neurology PA workflows?

Klivira integrates with EMR systems, often utilizing SMART on FHIR, to pull relevant clinical data directly from patient charts, order entries, and clinical templates. This seamless integration ensures that all necessary patient demographics, diagnoses, and treatment plans are accurately captured for prior authorization submissions.